Umbilical Cord Blood the blood cannot be prepared due to insufficient volume (the required minimum volume of Umbilical Cord Blood acquired is 10 mL), it shall be destroyed according to the procedure applicable at PBKM. PBKM shall not be responsible for the destruction of Umbilical Cord Blood excluded from preparation due to insufficient volume.
Umbilical Cord Blood blood collected from the umbilical cord vessels following the Child's cord separation and delivery of the placenta, which is genetically derived from the Child;
Umbilical Cord Blood. At time of storage: Within 2 years from the date of birth of the Child: (Only for Specimens listed in LifeCell Registry) Cord Blood Group & Rh Typing Cord Blood Volume Total Nucleated Cell Count Total Mononuclear Cell Count Total CD 34 Cell Count CD 34 Stem Cell Viability Hematocrit Sterility Hemoglobinopathies Human Leukocyte Antigen (HLA) Typing by Next-Generation Sequencing (NGS) At retrieval for transplant: Total Nucleated Cell Count Total Mononuclear Cell Count Total CD 34 Cell Count CD 34 Stem Cell Viability Hematocrit Sterility Colony Forming Unit (CFU) Assay HLA Typing by Next-Generation Sequencing (NGS) for Donor HLA Typing by Next-Generation Sequencing (NGS) for Recipient Inherited Diseases Testing by Next-Generation Sequencing (NGS) Maternal Blood: Blood Grouping & Rh Typing Anti - HBC CMV - IgG Nucleic Acid Test (HBV, HCV & HIV) CMV - IgM HIV I/II Syphilis Malaria Anti - HCV HBSAg HTLV I/II No additional cost to the Client for confirmatory tests Mesenchymal Stromal Cells / Stem Cells (MSC’s) At retrieval for transplant: Viable Mononuclear Count Sterility Mycoplasma Endotoxin Cell Morphology Cell Differentiation Potential Potency Flow Marker Positives: CD 90, CD 73, CD 105 Flow Marker Negatives: CD 34, CD 45, CD 14, CD 19, HLA-DR LC/DOM/CB-CA/09-24/012.9
Umbilical Cord Blood. Bio-Stor will actively market the Cryo-Cell cellular storage services throughout the United States. Bio-Stor will arrange enrollment of customers and specimens to be sent to the Cryo-Cell Clearwater, Florida lab facility (or other facility to be decided by Cryo-Cell) where they will be processed and/or stored. It is agreed that Cryo-Cell and Bio-Stor shall market to customers at identical processing and annual cellular storage fees. Bio-Stor must enroll, define and document customers who come from their marketing activities. Bio-Stor is responsible for paying all compensation, travel and marketing expenses for their staff. All hospitals signed by Bio-Stor will be responsible for all contact with their patient/clients and will arrange for the shipment of collected U-Cord blood and other specimens to a Cryo-Cell facility. The Cryo-Cell marketing plan provides that all participating hospitals now receive 25% of ongoing paid for cellular storage revenue. Bio-Stor has the right to alter this agreement for hospitals, etc that Bio-Stor enrolls through its marketing activity. If Bio-Stor reduces the hospitals 25% entitlement it can retain the difference to support hospital programs. For any specimens where processing is required (i.e. cord blood) which is generated by Bio-Stor marketing efforts Bio-Stor shall be paid marketing fees as follows:
